— Know what they know.
Not Investment Advice

PHAT NASDAQ

Phathom Pharmaceuticals, Inc.
1W: -11.3% 1M: -1.3% 3M: +1.4% YTD: -26.3% 1Y: +164.4% 3Y: -7.4% 5Y: -65.2%
$11.33
-0.25 (-2.16%)
 
Weekly Expected Move ±10.2%
$9 $11 $12 $13 $14
NASDAQ · Healthcare · Biotechnology · Alpha Radar Sell · Power 41 · $903.6M mcap · 50M float · 2.44% daily turnover · Short 49% of daily vol
Smart Money Score
Watch 25
Insider
Congress
ETF Holdings
Key Statistics
Market Cap$903.6M
52W Range3.92-18.31
Volume734,587
Avg Volume1,222,739
Beta0.57
Dividend
Analyst Ratings
8 Buy 1 Hold 0 Sell
Consensus Buy
Company Info
CEOSteven L. Basta
Employees427
SectorHealthcare
IndustryBiotechnology
IPO Date2019-10-25
100 Campus Drive
Florham Park, NJ 07932
US
877 742 8466
About Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

Recent Insider Trades

NameTypeSharesPriceDate
Parikh Asit M-Exempt 17,500 $4.95 2026-05-20
Parikh Asit D-Return 17,500 $4.95 2026-05-20
Topper James N A-Award 24,122 2026-05-19
Stenhouse Mark A-Award 24,122 2026-05-19
FIELDS HEIDI A-Award 24,122 2026-05-19

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms